Neutral
North Star Asset Management Inc. decreased its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 9.9% during the fourth quarter,...
Neutral
North Star Asset Management Inc. cut its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 9.9% in the fourth quarter, according to the co...
Bullish
Eli Lilly's experimental obesity drug, retatrutide, helped patients lose over 28% of their body weight in an 80-week trial, with some losing 30% or mo...
Neutral
Flynn Zito Capital Management LLC raised its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 117.3% during the 4th quarter, according to it...
Neutral
ProShare Advisors LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 7.6% in the 4th quarter, according to its most r...
Neutral
Profund Advisors LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 22.4% during the 4th quarter, HoldingsChannel ...
Neutral
Profund Advisors LLC lifted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 22.4% in the 4th quarter, according to its most recent Form...
Neutral
Handelsbanken Fonder AB trimmed its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 10.3% in the fourth quarter, according to its most r...
Neutral
Hartford Funds Management Co LLC grew its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 74.6% in the 4th quarter, according to the com...
Neutral
Eli Lilly and Company (LLY) announced that Daniel M. Skovronsky, chief scientific and product officer and president of Lilly Research Laboratories, wi...
Neutral
Swedbank AB increased its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 7.4% in the 4th quarter, according to its most recent 13F filing ...
Neutral
1ST Source Bank decreased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 5.1% during the fourth quarter, according to the company i...
Bullish
Eli Lilly has launched its Alzheimer's drug Donanemab, also known as Lormalzi, in India. The drug, priced at 91,688 rupees ($957) for a 350 mg vial, w...
Neutral
Stevens Capital Management LP lowered its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 74.3% during the fourth quarter, HoldingsChannel....
Neutral
This article provides details on the LILLY ELI & CO 5.7% 20-MAY-2066 bond (LLY6388974 FINRA), including its price chart, key terms like coupon rate an...
Eli Lilly and Company (NYSE:LLY) has released its Q1 2026 earnings call presentation, reporting strong financial results. The company's EPS of $8.55 b...
Neutral
Pacific Park Financial Inc. acquired a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) in the 4th quarter, according to the company in its...
Neutral
AMG National Trust Bank lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 7.0% during the fourth quarter, according to its most...
Bullish
Arlington Trust Co LLC significantly reduced its stake in Eli Lilly and Company (LLY) by selling 2,113 shares, decreasing its position by 92.8% in the...
Bullish
Following Eli Lilly and Company's (LLY) acquisition of Kelonia Therapeutics, analysts have reiterated a bullish outlook on the stock. Barclays maintai...